Navamedic ASA: Q2 and first half 2021 financial results
Oslo, 13 August 2021 – Navamedic ASA (OSE: NAVA) grew revenues by 56.7% in the second quarter of 2021 compared to the same quarter last year. The company reported revenues of NOK 66.0 million in the second quarter of 2021 with an EBITDA of NOK 4.3 million, driven by both new products, underlying growth and an improved revenue mix. The company reiterates its mid- to long-term ambition of building a NOK 500 million company.“We continue to deliver rapid growth for our specialty pharma product Mysimba and consumer health products Alflorex and ThermaCare. In parallel, we expand our product